Showing 3191-3200 of 6035 results for "".
- Leiters Now Integrated into Besse Medical’s Inventory Management Systemshttps://modernod.com/news/leiters-now-integrated-into-besse-medicals-inventory-management-systems/2476547/Leiters and Besse Medical announced that they have entered into a national agreement to provide ophthalmic medications that are compatible with Besse Medical’s inventory management systems, CubixxMD and PODIS Plus. This new agreement enables Leiters’ full suite of ophthalmic medicatio
- Lensar Laser System Receives FDA Clearance to Perform Micro Radial Incisions for Refractive Cataract Procedureshttps://modernod.com/news/lensar-laser-system-receives-fda-clearance-to-perform-micro-radial-incisions-for-refractive-cataract-procedures/2476537/Lensar announced it received 510(k) clearance from the FDA for the Lensar Laser System with Streamline IV, expanding the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post cataract surgery. “This indicat
- Ophtec Receives FDA Approval for RingJect Design Enhancementshttps://modernod.com/news/ophtec-receives-fda-approval-for-ringject-design-enhancements/2476536/Ophtec USA received FDA approval for the RingJect delivery system design optimization changes. Ophtec’s RingJect is a single use injector preloaded with the Ophtec Capsular Tension Ring (CTR). The Ophtec CTR is made of PMMA with patented compression molding technology, making for a durable
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- Bausch + Lomb Announces New Divisional Leadership in the UShttps://modernod.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/Bausch + Lomb announced the appointment of new leadership in its Pharmaceuticals and Consumer Health Care divisions in the United States. Yolande Barnard, formerly the vice president, marketing and sales, U.S. Neurology, Bausch Health, will now serve as vice president and general manager,
- US Military Develops Mobile Application to Treat Eye Injurieshttps://modernod.com/news/us-military-develops-mobile-application-to-treat-eye-injuries/2476479/The U.S. military medical researchers are developing a mobile application to connect combat medics with on-call ophthalmologists either in-theater or at a clinic to treat eye injuries of soldiers in the field, according to a
- STAAR Surgical Celebrates 1 Million Lens Milestone for Implantable Collamer Lenshttps://modernod.com/news/staar-surgical-celebrates-1-million-lens-milestone-for-implantable-collamer-lens/2476459/STAAR Surgical announced that more than 1 million Visian implantable collamer lenses (ICLs) have been implanted globally. Currently approved versions of the ICL available in more than 75 countries around the world address the explosive growth of myopia, the need for distance vision cor
- Alcon Debuts as Independent, Publicly Traded Companyhttps://modernod.com/news/alcon-debuts-as-independent-publicly-traded-company/2476453/After 8 years under Novartis ownership, Alcon is officially an independent, publicly traded company. On Tuesday, Alcon completed its separation from Novartis and its shares begin trading on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.” American depositary recei
- Ocular Therapeutix Announces Supplemental NDA Accepted by FDA for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-supplemental-nda-accepted-by-fda-for-dextenza/2476429/Ocular Therapeutix announced the FDA has accepted the filing of the supplemental new drug application (sNDA) for Dextenza (dexamethasone ophthalmic insert) to include the treatment of ocular inflammation following ophthalmic surgery in its label. The notice of acceptance confirms the FDA has comp
- Alcon Launches Expanded Parameters for Dailies AquaComfort Plus Toric Contact Lenseshttps://modernod.com/news/alcon-launches-expanded-parameters-for-dailies-aquacomfort-plus-toric-contact-lenses/2476425/Alcon has introduced a broader range of parameters for its Dailies AquaComfort Plus Toric contact lenses, giving it the most parameters of any daily disposable contact lens for people with astigmatism, according to a company news release. With this expansion, eye care professionals (ECPs) will ha